About Quotient Biodiagnostics
Quotient Biodiagnostics is a company based in Newtown Square (United States) founded in 2008. Quotient Biodiagnostics has raised $16.2 million across 7 funding rounds from investors including Galen Partners. The company has 178 employees as of March 31, 2022. Quotient Biodiagnostics offers products and services including MosaiQ, Alba, and LumiQ. Quotient Biodiagnostics operates in a competitive market with competitors including HORIBA, Boule Diagnostics, Entia, FYR Diagnostics and Mursla, among others.
- Headquarter Newtown Square, United States
- Employees 178 as on 31 Mar, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alivedx Suisse S.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16.2 M (USD)
in 7 rounds
-
Latest Funding Round
$36 M (USD), Debt – Conventional
Jun 29, 2018
- Investors
-
Employee Count
178
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Quotient Biodiagnostics
Quotient Biodiagnostics offers a comprehensive portfolio of products and services, including MosaiQ, Alba, and LumiQ.
Multiplex platform for faster in-vitro diagnostic results in labs.
Manual reagents for blood bank and immunohematology applications.
All-in-one system for autoimmune testing and lab efficiency.
People of Quotient Biodiagnostics
Unlock access to complete
Unlock access to complete
Funding Insights of Quotient Biodiagnostics
Quotient Biodiagnostics has successfully raised a total of $16.2M across 7 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $36 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Quotient Biodiagnostics
Quotient Biodiagnostics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Galen Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked |
Investor details for Quotient Biodiagnostics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Quotient Biodiagnostics
Investment portfolio details for Quotient Biodiagnostics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Quotient Biodiagnostics
Detailed financials for Quotient Biodiagnostics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quotient Biodiagnostics Comparisons
Peer comparison for Quotient Biodiagnostics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Quotient Biodiagnostics
Quotient Biodiagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as HORIBA, Boule Diagnostics, Entia, FYR Diagnostics and Mursla, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Multinational conglomerate
|
|
| Locked | Locked | Locked |
Provider of blood count analyzer for human and veterinary applications
|
|
| Locked | Locked | Locked |
Point-of-care devices for blood analysis are developed and provided.
|
|
| Locked | Locked | Locked |
In-vitro diagnostic tests for disease detection are provided.
|
|
| Locked | Locked | Locked |
Diagnostic devices for cancer detection are developed using nanostructures.
|
Detailed competitors of Quotient Biodiagnostics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quotient Biodiagnostics
Complete news archive for Quotient Biodiagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Quotient Biodiagnostics
Quotient Biodiagnostics was founded in 2008 and raised its 1st funding round 4 years after it was founded.
Quotient Biodiagnostics is headquartered in Newtown Square, United States. It is registered at Newtown Square, Pennsylvania, United States.
Quotient Biodiagnostics is a funded company, having raised a total of $16.2M across 7 funding rounds to date.
As of Mar 31, 2022, the latest employee count at Quotient Biodiagnostics is 178.
Manufacturer of immunohematology products for use in transfusion diagnostics. It focused on providing immunohematology products to hospitals and blood banks. Through its wholly-owned subsidiary, Alba Bioscience, Quotient offers research, development, and manufacturing of transfusion diagnostics products that traditionally have been sold worldwide either directly or by other major transfusion companies. It offers MosaiQ by Quotient, a comprehensive automation solution for blood grouping (for patients and donors) and donor disease screening.
Quotient Biodiagnostics's top competitors include HORIBA, Entia and Boule Diagnostics.
Quotient Biodiagnostics offers MosaiQ, Alba, and LumiQ.
Quotient Biodiagnostics has 1 investor. Key investors include Galen Partners.